key: cord-0794212-wgfdd3lm
authors: Garcia-Beltran, Wilfredo F.; Lam, Evan C.; St. Denis, Kerri; Nitido, Adam D.; Garcia, Zeidy H.; Hauser, Blake M.; Feldman, Jared; Pavlovic, Maia N.; Gregory, David J.; Poznansky, Mark C.; Sigal, Alex; Schmidt, Aaron G.; Iafrate, A. John; Naranbhai, Vivek; Balazs, Alejandro B.
title: Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
date: 2021-03-12
journal: Cell
DOI: 10.1016/j.cell.2021.03.013
sha: 2fad451c8e69de7cf6ea32c37feb791d20ce36d5
doc_id: 794212
cord_uid: wgfdd3lm

Vaccination elicits immune responses capable of potently neutralizing SARS-CoV-2. However, ongoing surveillance has revealed the emergence of variants harboring mutations in spike, the main target of neutralizing antibodies. To understand the impact of these variants, we evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against pseudoviruses representing 10 globally circulating strains of SARS-CoV-2. Five of the 10 pseudoviruses, harboring receptor-binding domain mutations, including K417N/T, E484K, and N501Y, were highly resistant to neutralization. Cross-neutralization of B.1.351 variants was comparable to SARS-CoV and bat-derived WIV1-CoV, suggesting that a relatively small number of mutations can mediate potent escape from vaccine responses. While the clinical impact of neutralization resistance remains uncertain, these results highlight the potential for variants to escape from neutralizing humoral immunity and emphasize the need to develop broadly protective interventions against the evolving pandemic.

Since the first described human infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December of 2019, nine vaccines have been approved for use in humans . Two of the vaccines currently in use worldwide, BNT162b2 (manufactured by Pfizer) and mRNA-1273 (manufactured by Moderna), are based on lipid nanoparticle delivery of mRNA encoding a prefusion stabilized form of spike protein derived from SARS-CoV-2 isolated early in the epidemic from Wuhan, China. Both of these vaccines demonstrated >94% efficacy at preventing coronavirus disease 2019 in phase III clinical studies performed in late 2020 in multiple countries (Polack et al. 2020; Baden et al. 2021) . However, the recent emergence of novel circulating variants has raised significant concerns about geographic and temporal efficacy of these interventions. Indeed, more recently One of the earliest variants that emerged and rapidly became globally dominant was D614G. While several studies demonstrated that this strain is more infectious (Korber et al. 2020; Yurkovetskiy et al. 2020a, [b] 2020; Plante et al. 2020; Zhou et al. 2020; Hou et al. 2020 ), we and others found that sera from convalescent individuals showed effective crossneutralization of both wildtype and D614G variants (Garcia-Beltran et al. 2021; Legros et al. 2021; Hou et al. 2020 ). However, recent genomic surveillance in the United Kingdom has revealed rapid expansion of a novel lineage termed B.1.1.7 (also known as VOC-202012/01 or 501Y.V1). B.1.1.7 harbors 3 amino acid deletions and 7 missense mutations in spike, including D614G as well as N501Y in the ACE2 receptor-binding domain (RBD), and has been reported to be more infectious than D614G (Santos and Passos 2021; Galloway et al. 2021; Liu et al. 2021) . Several studies have demonstrated that convalescent and vaccinee sera crossneutralize B.1.1.7 variants with only slightly decreased potency, suggesting that prior infection or vaccination with wild-type SARS-CoV-2 may still provide protection against B.1.1.7 variants J o u r n a l P r e -p r o o f (Wu et al. 2021; Muik et al. 2021; Shen et al. 2021; Rees-Spear et al. 2021; P. Wang et al. 2021 ). There have also been reports of SARS-CoV-2 transmission between humans and minks in Denmark with a variant called mink cluster 5 or B.1.1.298, which harbors a 2-amino acid deletion and 4 missense mutations including Y453F in RBD. Concerns relating to ongoing interspecies transmission resulted in the culling of over 17 million Danish minks to prevent further viral spread and evolution (Oude Munnink et al. 2021; Oxner 2020) . Another variant that recently emerged in California, United States, designated as B.1.429, contains 4 missense mutations in spike, one of which is a single L452R RBD mutation. The ability of B.1.1.298 and B.1.429 variants to evade neutralizing humoral immunity from prior infection or vaccination has yet to be determined.

Of particular concern is an E484K mutation in RBD, which was previously identified through in vitro selection experiments to escape from monoclonal antibodies (Baum et al. 2020) and was also recently identified through deep mutational scanning as a variant with the potential to evade monoclonal and serum antibody responses (Greaney et al. 2020 (Greaney et al. , 2021 . Novel variants arising from the B.1.1.28 lineage first described in Brazil and Japan, termed P.2 (with 3 spike missense mutations) and P.1 (with 12 spike missense mutations), contain this E484K mutation, and P.1 in particular also contains K417T and N501Y mutations in RBD. These strains have been spreading rapidly, and both P.2 and P.1 were recently found in documented cases of SARS-CoV-2 re-infection (Paiva et al. 2020; Faria et al. 2021; Resende et al. 2021; Naveca et al. 2021; Nonaka et al. 2021) .

Of greatest concern has been the emergence of multiple strains of the B.1.351 lineage (also known as 501Y.V2), which were first reported in South Africa and have since spread globally ). This lineage bears three RBD mutations, K417N, E484K, and N501Y, in addition to several mutations outside of RBD, and several reports have suggested that convalescent and vaccinee sera have decreased cross-neutralization of B.1.351 lineage variants (P. Wang et al. 2021; Wibmer et al. 2021; Wu et al. 2021; Hu et al. 2021) . A key limitation of several of these reports has been the use of single mutations or combinations of mutations that do not naturally occur. Regardless, the emergence of novel variants that appear to escape immune responses has spurred vaccine manufacturers to develop boosters for these spike variants ("Moderna Developing Booster Shot for New Virus Variant B.1.351" n.d.).

Here, we systematically assessed the neutralization potential of sera from a cohort of individuals who received one or two doses of the BNT162b2 (Pfizer) or mRNA-1273 (Moderna) vaccine against SARS-CoV-2 pseudoviruses that bear spike proteins found on circulating strains. We used our previously described high-throughput pseudovirus neutralization assay J o u r n a l P r e -p r o o f (Garcia-Beltran et al. 2021) J o u r n a l P r e -p r o o f

Since the first described case of SARS-CoV-2 infection in Wuhan, China in December of 2019, over 107 million confirmed infections have been documented (Coronavirus.jhu.edu), enabling viral diversification and the emergence of six distinct major lineages with numerous variants. A subset of these variants have been denoted as variants of concern by the World Health Organization given the presence of mutations with potential to increase transmissibility, virulence, or evade immune responses. We focused on variants of concern first described in the United Kingdom (B.1.1.7), Denmark (B.1.1.298), United States (B.1.429), Brazil and Japan (P.2 and P.1), and South Africa (B.1.351), most of which arose in late 2020 (Figure 1A-B) . Although the naturally arising mutations in these variants span the entire spike protein, they mainly occur in S1 and RBD, the main target of neutralizing antibodies ( Figure 1C and S1). After analyzing SARS-CoV-2 spike sequences deposited for each lineage in GISAID, we identified consensus sequence mutations that represent the dominant circulating strain for each lineage ( Figure 1D and S1). In the case of the B.1.351 lineage, we studied three of the dominant variants comprising the majority of deposited sequences, which we designated v1, v2, and v3. The three main RBD mutations of concern are: (i) N501Y, present in B. Although distantly related, SARS-CoV from the 2002 Hong Kong coronavirus outbreak and preemergent bat-derived WIV1-CoV both share ~76% spike homology to SARS-CoV-2 and were assessed to provide comparison to serologically distinct coronaviruses ( Figure 1A and 1D) .

We accrued a cohort of 99 individuals who received either one or two full doses of the BNT162b2 or mRNA-1273 vaccines, and used a luminescence-based lentiviral pseudovirus neutralization assay that we and others have previously validated (C. Wang et al. 2020; Ju et al. 2020; Pinto et al. 2020; Yang et al. 2020; Moore et al. 2004; Crawford et al. 2020; Garcia-Beltran et al. 2021) to assess neutralization of SARS-CoV-2 variants in a high-throughput system (Figure 2A-B) . This cohort was relatively young (median age: 33 years, range: 22 -73 years) and was 62.6% (62/99) female and 37.4% (37/99) male ( Figure S2) . We compared sera from 1220 pre-pandemic samples we had previously analyzed using the same assay (Garcia-Beltran et al. 2021) to our vaccinee cohort. Receiver operating characteristic analysis showed J o u r n a l P r e -p r o o f that the pseudovirus neutralization assay was able to accurately discriminate between nonvaccinated individuals and vaccinees ≥7 days following the second dose of BNT162b2 or mRNA-1273 (AUC = 0.9998), with a sensitivity of 100% and specificity of 99% using the limit of detection of the assay (pNT50 of 12) as the cut-off ( Figure S3 ). Between non-vaccinated and individuals receiving 1 dose of vaccine (or <7 days following the second dose), the sensitivity was reduced to 93% ( Figure S3 ). Sera obtained from individuals receiving 2 full doses of vaccine exhibited robust neutralization of wild-type SARS-CoV-2 pseudovirus, with BNT162b2 recipients achieving a median titer of 2,016 and mRNA-1273 recipients achieving a median titer of 762 (this difference was not statistically significant) ( Figure 3A ). Individuals who received only one dose of vaccine (or <7 days following the second dose) had significantly lower, but readily detectable, neutralization with a median titers of 167 for BNT162b2 and 208 for mRNA-1273 ( Figure 3C ). When comparing pseudovirus neutralization titer as a function of time postvaccination, we observed an expected increase in titer after the second dose ( Figure 3B ). The magnitude of neutralization correlated with total anti-RBD antibody levels; however, this correlation was poor given that most vaccinees reached the upper limit of detection of our ELISA ( Figure 3C ). Neither sex nor age appeared to significantly influence neutralization titers in our cohort ( Figure 3D-E) . Figure 4A-B) . This difference may be a consequence of the vaccine encoding the wild-type spike sequence, while many convalescent individuals in previous studies were likely infected with D614G variant SARS-CoV-2, given it had already become the globally dominant strain by the summer of 2020 (Lemieux et al. 2020; Korber et al. 2020 Figure 4C and S4A); for those who received 2 full doses of mRNA-1273, the mean fold decrease in neutralization relative to wild type was 2.3-fold for B.1.1.7, 1.3-fold for B.1.1.298, and 2.0-fold for B.1.429 (Figure 4D and S4A). However, neutralization of the Brazilian/Japanese P.2 variant, whose RBD contains an E484K mutation, was significantly decreased (5.8-fold for BNT162b2, p < 0.001; 2.9-fold for mRNA-1273, p < 0.01) ( Figure 4C-D and S4A ). This is in line with previous studies suggesting that the E484K mutation can evade polyclonal antibody responses (Greaney et al. 2020; Jangra et al. 2021 ) and has been found in cases of SARS-CoV-2 re-infection (Paiva et al. 2020; Faria et al. 2021; Resende et al. 2021; Naveca et al. 2021; Nonaka et al. 2021) . Similarly, neutralizing antibody responses were also significantly decreased for the Brazilian/Japanese P.1 strain (6.7fold for BNT162b2, p < 0.0001; 4.5-fold for mRNA-1273, p < 0.001), which harbors three mutations in RBD (K417T, E484K, and N501Y) and has also been found in cases of re-infection 

To better characterize the mutational context responsible for B.1.351 neutralization resistance, we explored the contribution of mutations located both within and outside of the RBD region of spike. Of note, many of the substitutions and deletions found in the B.1.351 lineage are in close structural proximity in the S1 domain ( Figure 5A ). However, 86.2% of available GISAID sequences of this lineage harbor these mutations in three distinct patterns represented by B.1.351 v1 (46.6%), v2 (31.6%) and v3 (8.0%). We created pseudoviruses in which the RBD regions of B.1.351 v1, v2, and v3 were reverted to their original wild-type Wuhan sequence (v1/wtRBD, v2/wtRBD, and v3/wtRBD) while retaining all other B.1.351 v1, v2, or v3 mutations.

Remarkably, neutralization assays conducted with sera from 24 individuals that received the 2dose BNT162b2 vaccine revealed that neutralization of B.1.351 v1, v2, and v3 in the absence of RBD mutations was comparable to that of D614G (Figure 5B-C) . A pseudovirus bearing only the three RBD mutations (K417N, E484K, and N501Y), largely, but not entirely, recapitulated the escape phenotype ( Figure 5B and 5D) . Despite this escape, antibodies exhibited reduced, but detectable, binding to mutant RBD protein harboring B.1.351 mutations (K417N, E484K, and N501Y) by ELISA, which correlated with K417N+E484K+N501Y pseudovirus neutralization (R 2 = 0.67, p < 0.0001) ( Figure 5E ). This suggests that vaccine-elicited antibodies capable of binding mutant RBD can retain the ability to neutralize RBD-mutant pseudoviruses.

Upon assessing the contribution of RBD versus non-RBD mutations towards escape, regression analyses provided statistical evidence of interaction between mutations within and outside of RBD in mediating escape from B.1.351 variants, consistent with synergistic (i.e. nonadditive) effects of these mutations (interaction statistics for B.1.351 v1 was p = 0.06, v2 was p < 0.0001, and v3 was p < 0.0001). These results suggest that while RBD mutations contribute the majority of the observed escape from vaccine-induced neutralization, they are more effective when in the context of additional mutations, particularly those found in B.1.351 v2 and v3 variants. One important aspect of immunity not addressed by our work is cellular immunity contributed by cytotoxic lymphocytes, including T and NK cells. Even in the absence of neutralizing humoral immunity, previous studies have suggested that cellular immunity can mitigate severe or prolonged infection (Le Bert et al. 2020) . In convalescent individuals, T-cell immunity would not be restricted to spike-derived epitopes, but also from other more abundant proteins such as nucleocapsid. As such, it would be reasonable to assume that T-cell-mediated immunity elicited by infection would remain largely intact for circulating variants including B.1.351. Indeed, although recent studies by Johnson & Johnson have demonstrated reduced overall efficacy in South Africa, there was substantially more protection against severe or fatal disease than for mild-to-moderate disease (Herper et al. 2021 ). However, with the exception of killed whole virus vaccines, all currently available vaccine designs only provide spike protein as the target immunogen, thus limiting T-cell immunity to spike epitopes. Notwithstanding, one recent study has demonstrated that mutations in spike epitopes do not impair T-cell responses despite escaping neutralizing antibodies (Skelly et al. 2021 ).

In summary, our data highlights the challenges facing all vaccines whose designs were finalized early in the pandemic and based on the sequence of the first-reported virus from Wuhan, China. Given the global scale and magnitude of the ongoing pandemic, including case reports of re-infection, it is clear that viral evolution will continue. It is possible that current vaccines will still provide clinical benefit against variants that exhibit poor cross-neutralization, such as P.1 and B.1.351, by reducing COVID-19 disease severity, but this has yet to be determined. Ultimately, it will be important to develop interventions capable of preventing transmission of diverse SARS-CoV-2 variants, including vaccine boosters that target these J o u r n a l P r e -p r o o f variants or technologies capable of eliciting or delivering broadly neutralizing antibodies.

The main focus of this study was to assess the potential of vaccinee sera to neutralize circulating SARS-CoV-2 variants. For this, we developed a high-throughput lentiviral pseudovirus-based in vitro neutralization assay that uses an engineered 293T-ACE2 cell line as target cells. As such, these cells restrict pseudovirus entry in an ACE2-dependent manner and lack other cell-surface proteins that may play a role in natural infection, such as TMPRSS2 ) or NRP1 (Cantuti-Castelvetri et al. 2020 . Additional studies are needed to assess the influence of these proteins on the serum neutralization titers measured. We did not assess other antibody-mediated functions such as complement deposition, antibodydependent cellular cytotoxicity, or antibody-dependent cellular phagocytosis, which may contribute to protection even in the absence of neutralizing antibodies. In addition, we did not assess the role of vaccine-elicited cellular immune responses mediated by T cells and NK cells, which are likely to play a key role in disease prevention for vaccine recipients. 

The authors declare no competing interests. 

Further information and requests for resources and reagents should be directed to and will be fulfilled by Alejandro Balazs (abalazs@mgh.harvard.edu).

Plasmids generated in this study will be available through Addgene. Recombinant proteins and antibodies are available from their respective sources.

This study did not generate sequence data or code. Data generated in the current study (including ELISA and neutralization) have not been deposited in a public repository but are available from the corresponding author upon request.

Use of human samples was approved by Partners Institutional Review Board (protocol 2020P002274). Serum samples from vaccine recipients that received one or two doses of the BNT162b2 or mRNA-1273 vaccine were collected in red top tubes. For each individual, basic demographic information including age and sex as well as any relevant COVID-19 history was obtained.

HEK 293T cells (ATCC) were cultured in DMEM (Corning) containing 10% fetal bovine serum (VWR), and penicillin/streptomycin (Corning) at 37°C/5% CO 2 . 293T-ACE2 cells were a gift from Michael Farzan (Scripps Florida) and Nir Hacohen (Broad Institute) and were cultured under the same conditions. Confirmation of ACE2 expression in 293T-ACE2 cells was done via flow cytometry.

To create variant spike expression plasmids, we performed multiple PCR fragment J o u r n a l P r e -p r o o f amplifications utilizing oligonucleotides containing each desired mutation (Integrated DNA Technology) and utilized overlapping fragment assembly to generate the full complement of mutations for each strain. Importantly we generate these mutations in the context of our previously described codon-optimized SARS-CoV-2 spike expression plasmid harboring a deletion of the C-terminal 18 amino acids that we previously demonstrated to result in higher pseudovirus titers. Assembled fragments were inserted into NotI/XbaI digested pTwist-CMV-BetaGlobin-WPRE-Neo vector utilizing the In-Fusion HD Cloning Kit (Takara). All resulting plasmid DNA utilized in the study was verified by whole-plasmid deep sequencing (Illumina) to confirm the presence of only the intended mutations.

To compare the neutralizing activity of vaccinee sera against coronaviruses, we produced lentiviral particles pseudotyped with different spike proteins as previously described (Garcia- analyzed on a Stratedigm S1300Exi Flow Cytometer.

Quantitative detection of total antibodies to SARS-CoV-2 receptor binding domain (RBD) was performed as previously described (Garcia-Beltran et al. 2021 ). Briefly, we used an indirect ELISA with a standard consisting of anti-SARS-CoV and -CoV-2 monoclonal antibody (CR3022) (IgG1 isotype). 96-well ELISA plates were coated with purified wild-type SARS-CoV-2 RBD.

Plates were blocked with BSA and washed. A seven-point standard curve was created using CR3022-IgG1 starting at 2 µg/mL by performing 1:3 serial dilutions with dilution buffer, and serum samples were diluted 1:100 with dilution buffer. Diluted samples and standards were added to corresponding wells and incubated for 1 h at 37°C, followed by washing. Total antibodies were detected with anti-human IgG+IgA+IgM (H+L)-HRP (Bethyl) diluted 1:25,000 for a 30 min incubation at room temperature. After washing, TMB substrate (Inova) was added to each well and incubated for 5-15 min before stopping with 1 M H 2 SO 4 . Optical density (O.D.) was measured at 450 nm with subtraction of the O.D. at 570 nm as a reference wavelength on a SpectraMax ABS microplate reader. Anti-RBD antibody levels were calculated by interpolating J o u r n a l P r e -p r o o f onto the standard curve and correcting for sample dilution; one unit per mL (U/mL) was defined as the equivalent reactivity seen by 1 µg/mL of CR3022. In assays where mutated RBD harboring K417N, E484K, and N501Y mutations was used, the exact same ELISA protocol was performed after confirming that our standard (CR3022-IgG1) bound to mutant versus wild-type RBD nearly identically.

Data and statistical analyses were performed using GraphPad Prism 9.0. 

AZD1222 Vaccine Met Primary Efficacy Endpoint in Preventing COVID-19

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Antibody Cocktail to SARS-CoV-2 Spike Protein Prevents Rapid Mutational Escape Seen with Individual Antibodies

Neuropilin-1 Facilitates SARS-CoV-2 Cell Entry and Infectivity

Escape of SARS-CoV-2 501Y.V2 Variants from Neutralization by Convalescent Plasma

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Emergence of SARS-CoV-2 B.1.1.7 Lineage -United States

COVID-19-Neutralizing Antibodies Predict Disease Severity and Survival

Comprehensive Mapping of Mutations to the SARS-CoV-2 Receptor-Binding Domain That Affect Recognition by Polyclonal Human Serum Antibodies

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain That Escape Antibody Recognition

New Data Shed Light on Efficacy of J&J's Single-Dose Covid Vaccine

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 D614G Variant Exhibits Efficient Replication Ex Vivo and Transmission in Vivo

Emerging SARS-CoV-2 Variants Reduce Neutralization Sensitivity to Convalescent Sera and Monoclonal Antibodies

The E484K Mutation in the SARS-CoV-2 Spike Protein Reduces but Does Not Abolish Neutralizing Activity of Human Convalescent and Post-Vaccination Sera

Human Neutralizing Antibodies Elicited by SARS-CoV-2 Infection

Tracking Changes in SARS-CoV-2 Spike: Evidence That D614G Increases Infectivity of the COVID-19 Virus

SARS-CoV-2-Specific T Cell Immunity in Cases of COVID-19 and SARS, and Uninfected Controls

A Longitudinal Study of SARS-CoV-2-Infected Patients Reveals a High Correlation between Neutralizing Antibodies and COVID-19 Severity

Phylogenetic Analysis of SARS-CoV-2 in the Boston Area Highlights the Role of Recurrent Importation and Superspreading Events

Moderna Developing Booster Shot for New Virus Variant B.1.351

Retroviruses Pseudotyped with the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Efficiently Infect Cells Expressing Angiotensin-Converting Enzyme 2

Neutralization of SARS-CoV-2 Lineage B.1.1.7 Pseudovirus by BNT162b2 Vaccine-Elicited Human Sera

Genomic Evidence of a Sars-Cov-2 Reinfection Case With E484K Spike Mutation in Brazil

Transmission of SARS-CoV-2 on Mink Farms between Humans and Mink and back to Humans

Denmark To Kill Up To 17 Million Minks After Discovering Mutated Coronavirus

Multiple Introductions Followed by Ongoing Community Spread of SARS-CoV-2 at One of the Largest Metropolitan Areas of Northeast Brazil

Structural and Functional Analysis of a Potent Sarbecovirus Neutralizing Antibody

Spike Mutation D614G Alters SARS-CoV-2 Fitness

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

The Impact of Spike Mutations on SARS-CoV-2 Neutralization

Spike E484K Mutation in the First SARS-CoV-2 Reinfection Case Confirmed in Brazil

Comparison of Four SARS-CoV-2 Neutralization Assays

The High Infectivity of SARS-CoV-2 B.1.1.7 Is Associated with Increased Interaction Force between Spike-ACE2 Caused by the Viral N501Y Mutation

SARS-CoV-2 Variant B.1.1.7 Is Susceptible to Neutralizing Antibodies Elicited by Ancestral Spike Vaccines

Affordable Luciferase Reporter Assay for Cell-Based High-Throughput Screening

Vaccine-Induced Immunity Provides

South Africa Suspends Use of AstraZeneca's COVID-19 Vaccine after It Fails to Clearly Stop Virus Variant

Sixteen Novel Lineages of SARS-CoV-2 in South Africa

A Human Monoclonal Antibody Blocking SARS-CoV-2 Infection

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization

SARS-CoV-2 501Y.V2 Escapes Neutralization by South African COVID-19 Donor Plasma

mRNA-1273 Vaccine Induces Neutralizing Antibodies against Spike Mutants from Global SARS-CoV-2 Variants

Development and Effectiveness of Pseudotyped SARS-CoV-2 System as Determined by Neutralizing Efficiency and Entry Inhibition Test in Vitro

Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant

SARS-CoV-2 Spike Protein Variant D614G Increases Infectivity and Retains Sensitivity to Antibodies That Target the Receptor Binding Domain

SARS-CoV-2 Spike D614G Variant Confers Enhanced Replication and Transmissibility

5% homology to SARS-CoV

J o u r n a l P r e -p r o o f HIGHLIGHTS • Numerous variants of SARS-CoV-2 harboring mutations in spike have arisen globally • mRNA vaccines elicit potent neutralizing activity against homologous pseudovirus • Cross-neutralization of strains with receptor binding domain (RBD) mutations is poor • Both RBD and non-RBD mutations mediate escape from vaccine-induced humoral immunity IN BRIEF Analyses of sera from individuals vaccinated with one or two doses of mRNA vaccines against 10 circulating variants of SARS-CoV-2, show that P.1 andB.1.351 in particular exhibit limited neutralization by vaccine-induced humoral immunity. This escape was found to be largely mediated by mutations in the receptor binding domain of SARS-CoV-2 spike.J o u r n a l P r e -p r o o f 13  18  20  26  69  70  80  138  145  152  190  215  242  243  244  246  417  452  453  484  501  570  614  655  681  692  701  716  982  1027  1118  1176  1229 wild

D614G · · · · · · · · · · · · · · · · · · · · · · G · · · · · · · · · · B.1.1.7 · · · · --· · -· · · · · · · · · · · Y D G · H · · I A · H · · B.1.1.298 · · · · --· · · · · · · · · · · · F · · · G · · V · · · · · · I B.1.429 I · · · · · · · · C · · · · · · · R · · · · G · · · · · · · · · · P.2 · · · · · · · · · · · · · · · · · · · K · · G · · · · · · · · F · P.1 · F N S · · · Y · · S · · · · · T · · K Y · G Y · · · · · I · F · B.1.351 v1 · · · · · · A · · · · G ---· N · · K Y · G · · · V · · · · · · B.1.351 v2 · F · · · · A · · · · G ---· N · · K Y · G · · · V · · · · · · B.1.351 v3 · · · · · · A · · · · · ---I N · · K Y · G · · · V · · · · · · SARS-CoV 75.6% homology to SARS-CoV-2